Search: onr:"swepub:oai:lup.lub.lu.se:851fdf00-5191-4912-92bb-29d6fa0669ee" >
Angiogenic factors ...
Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel
-
- Linderholm, B. K. (author)
- Karolinska Institutet
-
Lidbrink, E. (author)
-
Tallroth, E. (author)
-
show more...
-
Einbeigi, Z. (author)
-
Svensson, H. (author)
-
von Wachenfeldt, A. (author)
-
Norberg, B. (author)
-
Carlsson, L. (author)
-
Olsson, M. E. (author)
-
- Bergh, J. (author)
- Karolinska Institutet
-
- Wilking, Nils (author)
- Karolinska Institutet,Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine
-
- Hatschek, T. (author)
- Karolinska Institutet
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2013
- 2013
- English.
-
In: Breast. - : Elsevier BV. - 1532-3080. ; 22:6, s. 1142-1147
- Related links:
-
http://dx.doi.org/10...
-
show more...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Background: Several anticancer agents including paclitaxel have an inhibitory effect on angiogenesis. Aims: To compare the overall response rate and time to progression with changes in circulating angiogenic factors during palliative treatment with weekly paclitaxel. Material and methods: Patients with metastatic BC, ECOG 0-2, received weekly paclitaxel, concomitant with trastuzumab if HER2+ BC (n = 7). Circulating vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) were determined at base-line and before start of new course. Results: Fifty-five of 63 included patients were evaluable. The overall response rate including stable disease >= 24 weeks (CR + PD + SD) was obtained in 25 of the evaluable patients (45%). The median time to progression (TTP) was 5.3 months and overall survival (OS) 16.7 months. Patients with triple negative breast cancer (TNBC) showed a trend towards higher base-line VEGF compared with hormone receptor positive or HER2+ tumours and had shorter TTP. Significant differences in VEGF and bFGF levels at 12 weeks were found between patients with longer versus shorter TTP (VEGF: p = 0.046, bFGF: p = 0.005) and between patients gaining versus lacking clinical benefit (VEGF: p = 0.05, bFGF: p = 0.02). Conclusions: The clinical utility of circulating VEGF may be a useful tool for monitoring treatment efficacy. (C) 2013 Elsevier Ltd. All rights reserved.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)
Keyword
- Circulating VEGF and bFGF
- Palliative treatment
- Weekly paclitaxel
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
-
Breast
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Linderholm, B. K ...
-
Lidbrink, E.
-
Tallroth, E.
-
Einbeigi, Z.
-
Svensson, H.
-
von Wachenfeldt, ...
-
show more...
-
Norberg, B.
-
Carlsson, L.
-
Olsson, M. E.
-
Bergh, J.
-
Wilking, Nils
-
Hatschek, T.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Basic Medicine
-
and Pharmacology and ...
- Articles in the publication
-
Breast
-
The Breast
- By the university
-
Lund University
-
Karolinska Institutet